世界中医药
文章摘要
引用本文:周松,黄玲芳,李振莲,高艳周,刘铭.通心络胶囊联合西药治疗急性心肌梗死患者的疗效及对炎性因子的影响[J].世界中医药,2018,(01):.  
通心络胶囊联合西药治疗急性心肌梗死患者的疗效及对炎性因子的影响
Observation on Curative Effects of Tongxinluo Capsule Combined with Western Medicine in the Treatment of Patients with Acute Myocardial Infarction and Effects on Inflammatory Factors
投稿时间:2017-07-25  
DOI:10.3969/j.issn.1673-7202.2018.01.021
中文关键词:  通心络胶囊  西药  急性心肌梗死  疗效  炎性因子
English Keywords:Tongxinluo Capsule  Western medicine  Acute myocardial infarction  Curative effect  Inflammatory factors
基金项目:邢台市科技支撑计划项目(2015ZC219)
作者单位
周松,黄玲芳,李振莲,高艳周,刘铭 邢台市第三医院心内科邢台054000 
摘要点击次数: 1111
全文下载次数: 1055
中文摘要:
      目的:探讨通心络胶囊联合西药治疗急性心肌梗死患者的疗效及对患者炎性因子的影响。方法:选取2015年3月至2017年3月邢台市第三医院收治的急性心肌梗死患者94例,随机分为观察组与对照组,各47例。对照组采用西药治疗,观察组在对照组基础上结合通心络胶囊治疗。2组疗程均为14 d。比较2组治疗疗效,治疗前后心功能、炎性因子和心肌酶变化。结果:观察组总有效率(91.49%)高于对照组(72.34%)(P<0.05)。2组治疗后每搏心输出量(SV)、左心室射血分数(LVEF)增加而左心室收缩末期容积(LVEDV)降低(P<0.05);观察组治疗后SV、LVEF高于对照组而LVEDV低于对照组(P<0.05)。2组治疗后肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)和白介素-6(IL-6)降低(P<0.05);观察组治疗后TNF-α、CRP和IL-6低于对照组(P<0.05)。2组治疗后肌钙蛋白I(cTnI)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)降低(P<0.05);观察组治疗后cTnI、CK和CK-MB低于对照组(P<0.05)。结论:通心络胶囊联合西药治疗急性心肌梗死患者疗效显著,且可改善患者心功能、炎性反应和心肌酶。
English Summary:
      To observe curative effects of Tongxinluo Capsule combined with western medicine in the treatment of patients with acute myocardial infarction (AMI), and explore the effects on inflammatory factors. Methods: A total of 94 patients with acute myocardial infarction admitted to Xingtai Third Hospital from March 2015 to March 2017 were randomly divided into observation group and control group with 47 cases in each group. The control group was treated with western medicine, and the observation group was treated with Tongxinluo Capsule on the basis of the control group. The course of treatment of the two groups was both 14 days. The therapeutic effects of the two groups were compared. The changes of cardiac function, inflammatory factors and myocardial enzyme before and after treatment were compared. Results: The total effective rate of the observation group (91.49%) was higher than that of the control group (72.34%) (P<0.05). The indicators of stroke volume (SV) and left ventricular ejection fraction (LVEF) increased, and left ventricular end-systolic volume (LVEDV) decreased (P<0.05) of the two groups after treatment; the indicators of SV, LVEF in observation group after treatment were higher than that in the control group and LVEDV was lower than that in the control group (t=6.2713, 5.8286, 12.5245, P<0.05). Tumor necrosis factors (TNF-α) and C-reactive protein (CRP) and interleukin-6 (IL-6) decreased after treatment in two groups (observation group: t=19.3148, 19.7903, 20.5865, control group: t=8.4688, 8.3049, 7.9067, P<0.05); after treatment, TNF-α, CRP and IL-6 of the observation group were lower than those in the control group (t=10.1105, 11.3237, 13.7007, P<0.05). Troponin I (cTnI), creatine kinase (CK) and creatine kinase-MB (CK-MB) decreased after treatment in two groups (observation group: t=19.1719, 84.4794, 86.6657, control group: t=12.8121, 67.6642, 54.6297, P<0.05); after treatment, the indicators of cTnI, CK and CK-MB in observation group were lower than those in the control group (t=9.2587, 22.2531, 13.8418, P<0.05). Conclusion: Tongxinluo Capsule combined with western medicine is effective in the treatment of acute myocardial infarction and can improve the heart function, inflammatory reaction and myocardial enzymes, and has important research value.
查看全文  查看/发表评论  下载PDF阅读器